# Source note — ivermectin cancer/neurodegenerative dosing claims

Article: https://managingexpectations.net/blog/articles/ivermectin-cancer-neurodegenerative-dosing-claims-source-check.html
PBC companion: https://purebloodcanadians.com/blog/ivermectin-cancer-neurodegenerative-dosing-claims-source-check.html
Date: 2026-07-29
Lead X post: https://x.com/Ivermectin_hub/status/2082024291814834424

## Captured artifacts
- `video.info.json`, `video.en.vtt`, `transcript-clean.txt`, `oembed.json`, `page-x.html`, thumbnail `video.jpg`.
- PubMed/official source mirrors copied into this folder.

## Evidence classification
- Real preclinical anticancer literature exists.
- Published human oncology evidence remains weak/observational/contested; not a proven regimen.
- Gynecologic oncology review cautions against treatment use.
- Parkinson’s evidence located is mouse/pathway/preclinical, not human reversal.
- Alzheimer’s claims remain anecdotal in this pass; exact strong supporting paper not located.
- Horse-paste/megadose schedule is not supported and adds safety risk.

## Key sources
- PMC7505114 — Ivermectin, a potential anticancer drug derived from an antiparasitic drug.
- PubMed 40851910 — Ivermectin and gynecologic cancer: what’s the data?
- PubMed 32549918 — ovarian cancer cell-line/molecular paper.
- PubMed 42203321 — real-world observational cohort, with expression of concern.
- ClinicalTrials.gov NCT05318469.
- PubMed 32668263 and 27402173 for Parkinson/P2X4 preclinical signals.
- FDA Stromectol label; MedlinePlus/FDA animal-product and large-dose warnings.